Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between ≥18 and ≤75 years of age at the time of informed consent~* Signed informed consent~* Evidence of EoE defined by ≥15 peak eosinophils per HPF as measured from proximal and distal biopsies~* Subject-reported history of ≥3 episodes of dysphagia in the 7 days prior to Screening~* 7-day Global EoE Symptom Score \>3 at baseline and at screening~* Willing and able to adhere to study-related treatment regimens, procedures, and visit schedule~Exclusion Criteria:~* Have known contraindication, hypersensitivity, or intolerance to corticosteroids;~* Have any physical, mental, or social condition or history of illness or laboratory abnormality that in the Investigator's judgment might interfere with study procedures or the ability of the subject to adhere to and complete the study;~* Presence of oral or esophageal mucosal infection of any type;~* Have any mouth or dental condition that prevents normal eating;~* Have any condition affecting the esophageal mucosa or altering esophageal motility other than EoE;~* Use of systemic corticosteroids within 60 days prior to Screening, use of inhaled/swallowed corticosteroids within 30 days prior to Screening, or extended use of high-potency dermal topical corticosteroids within 30 days prior to Screening;~* Initiation of an elimination diet or elemental diet within 30 days before Screening (diet must remain stable after signing ICF);~* Morning serum cortisol level ≤5 μg/dL (138 nmol/L);~* Use of biologic immunomodulators in the 24 weeks prior to Screening;~* Use of calcineurin inhibitors or purine analogues, or potent cytochrome P450 (CYP) 3A4 inhibitors in the 12 weeks prior to Screening;~* Have a contraindication to or factors that substantially increase the risk of EGD or esophageal biopsy or have narrowing of the esophagus that precludes EGD with a standard 9 mm endoscope;~* Have a history of an esophageal stricture requiring dilatation within the previous 12 weeks prior to Screening;~* Have initiated, discontinued or changed dosage regimen of PPIs, H2 antagonists, antacids or antihistamines for any condition such as GERD or allergic rhinitis within 4 weeks prior to qualifying endoscopy. These drugs must remain constant throughout the study.~* A serum cortisol level \<18 μg/dL (497 nmol/L) at 60 minutes with adrenocorticotropic hormone (ACTH) stimulation test using 250 μg cosyntropin (i.e., a positive result on the ACTH stimulation test).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- APT-1011 1.5 mg HS (Type: EXPERIMENTAL): Placebo after breakfast, APT-1011 1.5 mg HS
- APT-1011 1.5 mg BID (Type: EXPERIMENTAL): APT-1011 1.5 mg after breakfast, APT-1011 1.5 mg HS
- APT-1011 3 mg HS (Type: EXPERIMENTAL): Placebo after breakfast, APT-1011 3 mg HS
- APT-1011 3 mg BID (Type: EXPERIMENTAL): APT-1011 3 mg after breakfast, APT-1011 3 mg HS
- Placebo BID (Type: PLACEBO_COMPARATOR): Placebo 30 minutes after breakfast and HS

Based on this trial design, predict the completion outcome and termination type (if applicable).